159 related articles for article (PubMed ID: 27436896)
1. Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.
Sbodio JI; Snyder SH; Paul BD
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8843-8. PubMed ID: 27436896
[TBL] [Abstract][Full Text] [Related]
2. Golgi stress response reprograms cysteine metabolism to confer cytoprotection in Huntington's disease.
Sbodio JI; Snyder SH; Paul BD
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):780-785. PubMed ID: 29317536
[TBL] [Abstract][Full Text] [Related]
3. Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease.
Paul BD; Sbodio JI; Xu R; Vandiver MS; Cha JY; Snowman AM; Snyder SH
Nature; 2014 May; 509(7498):96-100. PubMed ID: 24670645
[TBL] [Abstract][Full Text] [Related]
4. Cysteine metabolism and hydrogen sulfide signaling in Huntington's disease.
Paul BD
Free Radic Biol Med; 2022 Jun; 186():93-98. PubMed ID: 35550919
[TBL] [Abstract][Full Text] [Related]
5. Integrated stress response modulates cellular redox state via induction of cystathionine γ-lyase: cross-talk between integrated stress response and thiol metabolism.
Dickhout JG; Carlisle RE; Jerome DE; Mohammed-Ali Z; Jiang H; Yang G; Mani S; Garg SK; Banerjee R; Kaufman RJ; Maclean KN; Wang R; Austin RC
J Biol Chem; 2012 Mar; 287(10):7603-14. PubMed ID: 22215680
[TBL] [Abstract][Full Text] [Related]
6. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
7. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
8. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
9. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.
Dietrich P; Johnson IM; Alli S; Dragatsis I
PLoS Genet; 2017 Jul; 13(7):e1006846. PubMed ID: 28715425
[TBL] [Abstract][Full Text] [Related]
10. Mutant Huntingtin Derails Cysteine Metabolism in Huntington's Disease at Both Transcriptional and Post-Translational Levels.
Paul BD; Sbodio JI; Snyder SH
Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 36009188
[TBL] [Abstract][Full Text] [Related]
11. Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications.
Paul BD; Snyder SH
Front Mol Neurosci; 2019; 12():68. PubMed ID: 30941013
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells.
Oliveira AM; Cardoso SM; Ribeiro M; Seixas RS; Silva AM; Rego AC
Neurochem Int; 2015 Dec; 91():1-12. PubMed ID: 26476055
[TBL] [Abstract][Full Text] [Related]
13. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
14. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
15. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
[TBL] [Abstract][Full Text] [Related]
16. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
18. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
19. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
Moreno CL; Ehrlich ME; Mobbs CV
Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of copper ion mediated Huntington's disease progression.
Fox JH; Kama JA; Lieberman G; Chopra R; Dorsey K; Chopra V; Volitakis I; Cherny RA; Bush AI; Hersch S
PLoS One; 2007 Mar; 2(3):e334. PubMed ID: 17396163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
